Alloy M4 Face Cream Review: What the 34-Page Study Really Found

Where our money comes from, before you read a word: we are not an Alloy affiliate. We earn nothing if you buy M4, and nothing if you do not. Any compensated provider link on this page is labeled at the link.

---

Alloy M4 Face Cream Rx is a reasonable premium buy for hydration and smoother-looking texture if you accept a compounded 0.3% estriol prescription and a $150 three-month subscription. The trial found a 26% machine-measured hydration increase, but not a machine-measured elasticity change. The famous 88% came from the investigator’s visual and tactile rating.

Best for: women in perimenopause or menopause who already use daily sunscreen, want hydration and texture support, can comfortably sustain the cost, and value the strongest finished-product study we found in this direct-to-consumer category.

Not for you if: you need an FDA-approved product, want a proven wrinkle indication, need the lowest price, cannot tolerate an automatic subscription, or need a clinician who already knows your cancer, clotting, liver, pregnancy, or pigment history before a hormone-containing skin product is considered.

Alloy M4 Face Cream Rx at a glance

Decision fact	What we verified
What it is	Prescription facial cream containing estriol in a fragrance-free moisturizing base
Strength	0.3% estriol, published in Alloy’s clinical study report, but not stated on the standalone retail product page
Regulatory status	Compounded prescription drug. Not FDA-approved. FDA states that no FDA-approved drug contains estriol
Listed price	$150 for a three-month supply, verified on Alloy’s product page on August 11, 2026
Retail quantity	Standalone product page says one bottle/three-month supply; an Alloy bundle page lists the face cream as 45 g
Study evidence	One sponsor-funded, 12-week, randomized, double-blind, vehicle-controlled study; 90 women enrolled and 86 completed
Strongest objective result	Skin water content increased 26% from baseline at week 12 in the estriol group, p=0.001
Machine-measured elasticity	No consistent change in the estriol, estradiol, or vehicle group
The 88% claim	Investigator-rated elasticity at week 12 versus vehicle — not 88% of women and not an instrument-measured 88% increase
Refund window	Request within 30 days of receiving the first shipment of that product; products cannot be returned
Subscription timing	Cancel the subscription at least 7 days before the period ends; pause/cancel a shipment at least 5 business days before processing
Best reason to choose it	The most transparent finished-product trial we found among the compared direct-to-consumer estriol face creams
Main reason to skip it	You want an FDA-approved medication, published retail dose math, a lower upfront commitment, or stronger wrinkle evidence

---

Before you read the rest

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

A face cream can be a small decision inside a bigger one.

The right online HRT provider is not the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer cannot resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care is not the right starting point — before your first consult.

---

What is Alloy M4 Face Cream Rx?

M4 Face Cream Rx is Alloy Health’s prescription facial cream containing 0.3% estriol in a fragrance-free moisturizing base. Alloy lists it at $150 for a three-month supply, includes ongoing clinician messaging while the prescription is active, and requires an online medical review before a prescription can be issued.

M4 stands for Mega Miracle Menopause Moisturizer. The name sounds like a cosmetic. The product is not one.

It is a prescription drug, not an over-the-counter moisturizer. A licensed clinician has to review your history and decide whether to prescribe it. The retail page identifies estriol as the active ingredient, and Alloy’s clinical study report identifies the concentration as 0.3%.

It is not systemic menopause treatment. M4 is a prescription topical estrogen product used on facial skin. It is not sold to treat hot flashes, night sweats, bone loss, vaginal dryness, painful sex, or the other symptoms that systemic or vaginal menopause therapies are designed to address.

It is compounded, not FDA-approved. That distinction is not a side note. It determines what has and has not been reviewed by a regulator, and we deal with it directly below.

What is actually in the cream?

Alloy publishes this ingredient list on the standalone M4 page:

Estriol, C12-15 alkyl benzoate, caprylic/capric triglyceride, cetyl alcohol, ethylhexylglycerin, glycerin, glyceryl stearate, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, oleic acid, olive fruit oil, PEG-100 stearate, phenoxyethanol, dimethicone, polymethylsiloxane, water, stearic acid, trolamine, and vitamin E acetate.

That level of base-formula disclosure is useful. It also corrects a common oversimplification: Alloy is not the only seller publishing an ingredient list. Midi publishes its active formulation and full ingredients, and Winona now publishes the active and inactive ingredients in its compounded estriol-plus-tretinoin cream. The public Wisp page does not disclose the estriol strength or bottle volume.

The numbers Alloy leaves out on the standalone product page are the ones that determine exposure and unit cost: the 0.3% concentration and the net quantity. You can find each elsewhere in Alloy’s own materials, but a shopper should not have to cross-examine a study PDF and a bundle page to identify them.

---

Does Alloy M4 face cream actually work?

The strongest evidence is Alloy’s 12-week randomized, double-blind, three-arm study in 90 postmenopausal women. It found a statistically significant 26% increase in machine-measured skin water content with 0.3% estriol. It did not find a consistent machine-measured elasticity change, and wrinkles were not among the estriol group’s significant investigator-rated wins.

This study is genuinely better than the evidence package we found on the public product pages of the compared direct-to-consumer estriol creams. It is also sponsor-funded, small, short, and much easier to overstate than the ads make it look.

What the study was

Study detail	Verified description
Protocol	DCS-102-23
Report date	June 30, 2024
Investigator/site	Zoe Diana Draelos, MD; Dermatology Consulting Services, PLLC
Ethics review	Allendale Institutional Review Board
Sponsor	Alloy Women’s Health
Design	Randomized, double-blind, single-site, three-arm, vehicle-controlled
Groups	M4 base alone; base + 0.3% estriol; base + 0.01% estradiol
Participants	90 enrolled; 86 completed; 30 assigned to each arm
Population	Healthy postmenopausal women ages 50–60 with mild-to-moderate photoaging; Fitzpatrick I–VI
Hormone-therapy history	Participants had never taken systemic HRT and could not be receiving HRT during the study
Studied application	Three pumps, approximately 1 mL, nightly to the face — including under/around the eyes — and neck
Duration	12 weeks
Measures	Corneometry, mechanical elasticity testing, TEWL, melanin readings, serum estriol/estradiol, investigator grading, participant grading, standardized photography

“Vehicle-controlled” matters. One group used the same cream base without estriol or estradiol. That gives the trial a real chance to separate the hormone from the moisturizer carrying it.

And Alloy published the full 34-page report — not a two-sentence press release, not only the flattering graph, and not only the percentage that sells. That deserves credit.

The Alloy M4 claim-to-evidence audit

Public-facing claim	What the study actually measured	What held up	What did not
“88% improvement in elasticity”	Investigator’s 5-point visual/tactile grade, estriol versus vehicle at week 12	Investigator grade favored estriol	The mechanical elasticity instrument found no consistent change
“70% improvement in hydration”	Investigator’s ordinal hydration grade, estriol versus vehicle at week 12	Investigator grade favored estriol	It is not the same endpoint as the objective hydration device
Hydration improves	Corneometer measurement of skin water content	26% increase from baseline, p=0.001; vehicle did not significantly improve	The study lasted only 12 weeks and did not compare M4 with a commercial moisturizer
Improves firmness	Investigator’s ordinal firmness grade	Estriol improved 15% versus its own baseline	Estriol firmness was not listed among the significant estriol-versus-vehicle differences
Reduces wrinkles	Investigator and participant ordinal grades	The trial assessed wrinkles	Wrinkles were not listed among the estriol group’s statistically significant wins
Does not affect blood estrogen	Serum estriol and estradiol at baseline and week 12	Estriol did not change significantly; the report said the estradiol change was within lab error	Two time points in a 12-week study do not prove zero absorption for every user or long-term use
No pigmentation increase	Instrumental cheek melanin readings	No increase; the report described a slight 1–2% decrease	This does not settle long-term melasma risk
Well tolerated	Investigator and participant tolerability plus adverse events	No study-related tolerability issue or adverse event occurred during 12 weeks	Thirty estriol participants over 12 weeks is not a long-term safety database

What actually improved

Hydration, by machine. The corneometer recorded a 26% increase in skin water content in the estriol group at week 12, with p=0.001. The estradiol group increased 20%, with p=0.007. The vehicle group did not show a statistically significant increase.

That is the cleanest and most defensible M4 result. It is objective, it is statistically significant, and it separates the estriol formula from its own base.

Visible and tactile appearance, by the investigator. At week 12, the investigator’s between-group ratings favored estriol over vehicle for radiance, tactile and visual roughness, hydration, elasticity, and overall appearance. The differentiation did not appear at weeks 4 or 8.

Pigmentation did not increase during the study. Instrumental melanin readings showed a slight 1–2% decrease in the estriol and estradiol arms rather than an increase.

Serum estriol did not significantly change. Blood was tested at baseline and week 12. The report found no statistically significant estriol increase and described the small estradiol change as within laboratory error.

No adverse events occurred during the 12-week trial. The investigator identified no tolerability problems in any arm, and participants did not report study tolerability issues.

What did not improve — or did not prove what the marketing implies

Mechanical elasticity did not change consistently. The cutometer-style instrument found no consistent change in the estriol, estradiol, or vehicle group. That result sits in the same report as the 88% investigator-grade claim.

Wrinkles were not a significant estriol win. Fine lines, wrinkles, and pores do not appear in the report’s list of significant estriol improvements versus baseline or significant estriol-versus-vehicle differences.

Firmness did not beat the base in the estriol arm. Investigator-rated firmness improved 15% within the estriol group compared with its own baseline, but the report does not list firmness among the significant estriol-versus-vehicle results. The estradiol arm — a different formula — did beat vehicle on firmness.

The barrier measurement moved in the wrong direction. The estriol group had a statistically significant 13% increase in transepidermal water loss, or TEWL, at week 12, p=0.027. Higher TEWL means more water leaving the skin. The estradiol and vehicle arms were described as barrier-neutral.

That is not the same as saying M4 damaged anyone’s skin. No irritation or adverse event occurred in the study. It is a contradictory instrument finding: corneometry said the upper skin held more water, while TEWL said more water was escaping through the barrier. Both belong in the decision.

And then there is the sentence everyone quotes incorrectly

The report says participants were “unable to distinguish between the estriol, estradiol, and placebo/vehicle control, as they only had exposure to one product.” It then says all three products received excellent ratings.

That does not mean each woman tried all three creams and failed a blind identification test. This was a parallel-group trial. Each participant used one assigned formula.

What it does mean is still uncomfortable for a $150 prescription: the participant-rated questionnaires did not meaningfully separate the three arms, and all groups rated the product they received highly. The objective hydration machine did separate estriol from vehicle. The women’s own ratings did not give the same clean separation.

That does not make the cream worthless. It tells you what you are buying: a product with a real hydration signal and encouraging investigator-rated appearance results, not a transformation so obvious that blinded users independently identified the active cream.

What the study cannot tell you

The participants were 50–60, postmenopausal for at least a year, and had never taken systemic HRT. They could use established non-anti-aging skincare and cosmetics, but the protocol excluded retinoids, retinol, vitamin A derivatives, vitamin C, AHAs, salicylic acid, medicated facial products, recent Botox or fillers, and recent peels, laser, or dermabrasion.

So the study did not test the most common real-life stack: M4 plus a retinoid, vitamin C, exfoliating acids, injectable treatments, or a systemic estrogen patch.

The sponsor chose the 90-person sample size. The report does not describe a formal power calculation. It tested many outcomes at four time points and does not describe a correction for multiple comparisons. That does not erase the findings. It is why a single large relative percentage should not be allowed to carry the whole verdict.

---

What does Alloy’s “88% improvement in elasticity” actually mean?

The 88% is a week-12 comparison between the estriol and vehicle groups on the investigator’s 5-point visual and tactile elasticity grade. It is not an 88% increase measured by the elasticity instrument, not an 88% change from baseline, and not 88% of participants reporting improvement.

This is the most important translation on the page.

Both findings are in the same report:

• The investigator’s ordinal grade favored estriol over vehicle by 88% at week 12.
• The mechanical elasticity test found no consistent change in any group.

Those measures are not interchangeable. A clinician’s visual and tactile impression can improve while a device measuring physical stretch and rebound does not. Hydration can change how skin looks and feels without producing the same movement in an instrument-based elasticity parameter.

So the honest sentence is:

At week 12, the investigator’s visual and tactile elasticity rating favored 0.3% estriol over the vehicle by 88%; the study’s mechanical elasticity test did not show a consistent change.

The sentence that goes too far is:

M4 increases your skin’s elasticity by 88%.

The public page goes one step further

Alloy’s skincare category page says “88% saw improved elasticity with M4 Face Cream.”

That wording makes the number sound like the share of women who noticed a result. It was not. The 88% came from an investigator’s between-group ordinal comparison.

And the study report says the participants — each exposed to one assigned product — gave excellent ratings across all three groups without meaningful product separation.

We do not need to invent bad intent to call the wording wrong. A marketing team compressed a technical result into a line that changes who appears to have measured it. On a page selling a $150 prescription, the endpoint and the observer matter.

The 70% hydration claim needs the same translation

Alloy also advertises a 70% improvement in hydration. That is the investigator’s ordinal grade for estriol versus vehicle at week 12.

The objective hydration result was different: the corneometer measured a 26% increase from the estriol group’s own baseline.

Both can be true. They answer different questions. Whenever a skincare page gives you a percentage, ask four things:

1. Measured by whom — participant, investigator, or instrument?
2. Compared with what — baseline, vehicle, or another active product?
3. At what time point?
4. Was the difference statistically significant?

That four-question check is the difference between reading the ad and reading the study.

---

Is Alloy M4 better than a really good moisturizer?

M4 beat its own cream base on objective skin hydration at week 12, so the study supports an effect beyond that vehicle. It does not show that M4 beats your current moisturizer, because no commercial moisturizer was tested. Participant ratings also did not meaningfully separate the active creams from the vehicle.

This is the question underneath the question.

The vehicle was not an inert nothing. It was the M4 moisturizing base without estriol or estradiol. It contained ingredients such as glycerin and dimethicone. Under the FDA’s over-the-counter skin-protectant rule, glycerin and dimethicone can serve as active skin protectants at specified concentrations — but Alloy does not publish their concentrations in M4, so we cannot call the formula an OTC skin-protectant drug or assume it meets those ranges.

What we can say is simpler: the base was a real moisturizer, and all groups liked their assigned product. That makes the vehicle a meaningful test rather than a straw-man control.

M4 still cleared that test on the objective hydration measurement. The estriol group gained 26%; the vehicle group did not significantly improve. That is a real reason to choose M4 over the exact same base without estriol.

Whether it beats the moisturizer already working on your bathroom shelf is unanswered.

Where FDA-approved tretinoin fits — and where it does not

Renova 0.02% is an FDA-approved tretinoin product with a narrow indication: it may reduce fine facial wrinkles when used as an adjunct to comprehensive skincare and sun avoidance. Its current label also says it does not remove wrinkles, repair sun-damaged skin, or reverse photoaging, and that it does not work for everyone.

That approval belongs to Renova’s specific 0.02% product and label. It does not transfer to every compounded cream containing tretinoin. A compounded estriol-plus-tretinoin formula is still a compounded product that has not been FDA-approved as a finished medication.

That distinction matters when comparing Alloy with Winona. Winona combines estriol and tretinoin, which may be attractive when fine lines are the priority. But Winona’s final compounded combination is not Renova, the active strengths are not published on the product page, and FDA states there is no FDA-approved estriol drug.

▸ You came here for permission. Here it is.

If you have read the study limits and are still thinking, fine — my goal is hydration and smoother texture, I use sunscreen, and $150 every three months is comfortable — that is a coherent decision. You are choosing the strongest finished-product evidence package we found in this narrow seller category, not buying an 88% miracle.

→ See Alloy’s current M4 price and start the skin assessment

Prescription required. A clinician decides whether treatment is appropriate. Listed price at last verification: $150 for a three-month supply. We do not earn money from this link.

---

Is Alloy M4 FDA approved?

No. M4 is a compounded prescription drug and is not FDA-approved. FDA states that no FDA-approved drug contains estriol. Compounded drugs can meet an individual patient need, but FDA does not review them for safety, effectiveness, or quality before marketing the way it reviews approved products.

This is legal. It is not the same as approved.

Compounded means a pharmacy prepares a medication under the conditions that apply to pharmacy compounding. Oversight depends on the type of compounder: traditional 503A pharmacies are primarily overseen by state boards, while FDA has additional oversight of registered 503B outsourcing facilities. Either route is different from FDA approval of a finished drug.

Not FDA-approved means FDA has not reviewed this exact finished formulation and labeling and determined that it is safe and effective for this use. It also means the approved manufacturing and quality framework attached to a New Drug Application does not apply in the same way.

That does not make the prescription illegal, fake, or automatically poor quality. It means the assurance level is different, and the provider should say so plainly.

Where Alloy says it — and where it does not

On August 11, 2026, the standalone M4 product page described M4 as prescription, identified estriol as the active ingredient, and linked to a broader “Alloy Promise.” The words “compounded” and “not FDA-approved” did not appear in the visible M4 product-page copy we reviewed.

Alloy does use the word “compounded” elsewhere on its site, including for other skincare and medication categories. Its Terms of Use also name the pharmacies Alloy uses: Curexa Pharmacy, BLEND Pharmacy, and Gogo Pharmacy. The terms do not say which one will dispense an individual M4 prescription; that can be confirmed during the prescription and fulfillment process.

A shopper should not have to infer regulatory status from a different page. The clean disclosure would be one line next to the price:

Compounded prescription product; not FDA-approved.

Until Alloy places that where the decision happens, we will.

The Winona comparison exposes the same category problem

Winona’s estriol-plus-tretinoin page says the active ingredients estriol and tretinoin are FDA-approved, then says the final medication is compounded. The tretinoin statement is incomplete and the estriol statement is wrong: FDA states that no FDA-approved drug contains estriol.

Some FDA-approved drugs contain tretinoin. That does not make an undisclosed-strength compounded combination FDA-approved, and it does not allow approval to be transferred ingredient-by-ingredient to the finished cream.

This is why the article keeps three ideas separate every time:

1. An ingredient may appear in an FDA-approved product.
2. A particular branded or generic finished drug may be FDA-approved for a specific indication.
3. A compounded finished formula is not FDA-approved.

M4 belongs in the third category.

---

How much does Alloy M4 cost?

Alloy lists M4 Face Cream Rx at $150 for one bottle described as a three-month supply. That is $50 per month only if the bottle lasts the full three months. The standalone page does not offer a one-month size, and the current retail page does not display a separate skincare consultation charge. Confirm the final first-order total before payment.

The useful price is not “starting at.” It is the amount you are asked to commit today.

Cost question	Verified answer
Listed M4 price	$150
Supply label	Three months
Upfront commitment	$150 before any applicable tax or checkout-specific charge
Advertised monthly equivalent	$50/month if it lasts 90 days
One-month trial size	Not offered on the product page
Shipping	Product page says free delivery
Insurance	Alloy does not bill this as an insurance product; cash-pay model
HSA/FSA	Product page displays HSA/FSA Eligible; plan eligibility and reimbursement are still determined by the account administrator
Subscription	Continuous and auto-renewing unless canceled under Alloy’s terms
Separate first-order consult fee	No separate charge is displayed on the M4 page; verify the final checkout total before submitting payment

That last line is intentionally not guessed. The M4 page says “Includes $0 unlimited doctor access,” but ongoing access and an intake fee are not the same concept. Alloy’s terms say posted prices can contain provider, pharmacy, platform, and support components. The only production-safe statement is the one the page actually supports: M4 is listed at $150; confirm the final charge before payment.

We keep bundles, promotions, and deeper annual math on the dedicated Alloy M4 face cream cost page. This review owns the evidence and the verdict.

Is $50 a month a fair shorthand?

Only as a label, not a verified use-cost calculation.

Alloy sells the bottle as three months. But its public application instructions conflict, and its standalone retail page does not publish the pump output. You cannot independently verify the number of nights from the retail page alone.

So the honest phrasing is:

$150 per shipment; advertised as a three-month supply.

Not:

Exactly $50 per month at any dose.

---

How much M4 do you use, and will one bottle last three months?

Follow the dispensing label and prescriber’s instructions. Alloy’s public materials currently give three different reference amounts: one pump in a help-center answer, two pumps in its skincare routine, and three pumps in the clinical study. The study dispenser was 45 mL; an Alloy retail bundle page lists the face cream as 45 g. Those units are not interchangeable.

This sounds like packaging trivia. It determines the actual daily estriol amount and the real cost of use.

0.3% is a concentration, not a dose. The amount applied determines how much estriol is placed on the skin. One pump versus three pumps is not a copywriting detail.

The study-versus-retail dose ledger

Input	What the source says	What you can safely conclude
Study concentration	0.3% estriol	This states strength, not the amount applied per night; retail dose still requires the prescribed amount and retail pump-output data
Study instruction	Three pumps, approximately 1 mL, nightly to face and neck	This was the research protocol, not automatically every retail prescription
Study dispenser	45 mL	Study packaging held 45 mL
Study pump output	0.3 mL per pump	Three pumps equaled 0.9 mL by the stated pump output and were rounded in the report to approximately 1 mL
Study applications per 45 mL dispenser	45 ÷ 0.9	Approximately 50 studied applications per dispenser before any priming or residual loss
Retail standalone page	One bottle, three-month supply	It does not publish net quantity or pump output
Alloy retail bundle page	M4 Face Cream Rx, 45 g	Retail quantity is stated by weight on that page, not volume
Alloy skincare routine	Two pumps in the evening	Public routine differs from the study protocol
Alloy help-center answer	One pump for face and neck	Public advice differs again

The original draft tried to turn the study’s 45 mL package into retail-night estimates. That is not defensible. A 45 g retail bottle is not automatically 45 mL, and a retail pump is not proven to dispense the study pump’s 0.3 mL.

The corrected conclusion is sharper:

Alloy sells M4 as a three-month supply, but its public retail pages do not provide enough consistent dose and dispenser data for a shopper to reproduce that claim mathematically.

We are not saying the bottle cannot last three months. We are saying the public evidence does not let you independently calculate it.

Ask these three questions before you pay

1. How many pumps should I use for the areas on my prescription label?
2. What is the net weight and the expected number of full pumps in my retail bottle?
3. Is the formula and dispenser I am receiving the same as the one used in protocol DCS-102-23?

One written answer from Alloy resolves more than ten paragraphs of online speculation.

---

Does estriol get into your bloodstream, and can you use M4 with HRT?

Alloy’s study found no statistically significant serum estriol change from baseline to week 12. That supports minimal measured systemic exposure under the studied conditions. It does not prove that no estriol enters the bloodstream, that exposure is zero for every user, or that long-term use alongside systemic HRT has been established.

Alloy’s product page says topical estriol stays on the skin’s surface, does not enter the bloodstream, and can be used with or without HRT because it does not affect blood estrogen levels.

The study supports a narrower sentence.

What was measured

• Serum estriol and estradiol were measured at baseline and week 12.
• Serum estriol did not change significantly.
• Estradiol rose from 12.92 to 16.60 in the report’s table; the report described that change as within laboratory error.
• The estriol arm contained about 30 women and the trial lasted 12 weeks.

A 1993 facial-skin study also evaluated systemic effects over three months in 17 women total: eight used 0.3% estriol and nine used 0.01% estradiol. That is not a 17-woman estriol-only study, and the distinction belongs in the article.

Together, the small studies are reassuring about short-term measured hormone levels under their specific protocols. They do not establish zero absorption in every body, at every application amount, over years.

Can you use M4 with an estrogen patch, pill, gel, or spray?

Alloy markets M4 for use with or without hormone therapy. But every participant in the M4 trial had never taken systemic HRT, and current HRT use was an exclusion criterion.

So the trial cannot tell you:

• whether M4 adds visible benefit on top of systemic estrogen;
• whether serum patterns differ when both are used;
• whether the studied dose is the best dose for someone already using estrogen elsewhere; or
• whether a particular cancer, clotting, liver, bleeding, or medication history changes the decision.

That does not automatically mean the combination is unsafe. It means the company’s own trial did not answer the combination question.

Tell the prescriber every estrogen-containing product you use, including vaginal estrogen, systemic HRT, compounded hormones, and any hormone-containing skincare. Let the prescriber own the decision instead of the ad.

When an online skincare intake is not enough

Do not use this page as clearance to start a hormone-containing product if you have a personal history of breast, uterine, ovarian, or another estrogen-sensitive cancer; take tamoxifen or an aromatase inhibitor; have unexplained or postmenopausal bleeding; have a significant clotting, stroke, or liver history; are pregnant, breastfeeding, or trying to conceive; or have another condition your specialist is actively managing.

Those groups were not the evidence base behind the 12-week M4 result. Get explicit guidance from the clinician who knows the relevant history — including an oncology team when applicable.

---

Can Alloy M4 cause melasma or dark spots?

The M4 trial found no increase in instrumental melanin readings over 12 weeks and described a slight 1–2% decrease. That is reassuring for the studied period. It does not prove M4 cannot worsen melasma. Midi’s competing estriol page warns that estriol may enhance pigmentation, and the broader literature has not established a consistent link.

This is not a reason to scare women away from the product. It is a reason to stop pretending the pigment question is closed.

Alloy’s trial gives M4 a favorable short-term signal: no measurable pigmentation increase in healthy women with mild-to-moderate photoaging.

But the category itself is not consistent:

• Midi, which sells a 0.3% estriol face cream, warns that estriol may enhance pigmentation and may exacerbate melasma.
• A recent peer-reviewed dermatology review reported hyperpigmentation in some estradiol-treated participants in prior research but said no consistent association had been established.
• Hormonal history is relevant to melasma, and 12 weeks is short for a long-term pigment question.

So the production-ready conclusion is not “M4 causes melasma,” and it is not “M4 cannot cause melasma.” It is:

M4 showed no 12-week pigmentation signal in its trial. If you have active melasma, a strong history of hormone-triggered pigment, or are treating pigmentation with a dermatologist, ask that dermatologist before starting it.

No purchase link belongs in this section.

---

What about the M4 eye cream, serum, and body treatment?

Alloy sells four prescription estriol skincare products under the M4 name. The face cream has the strongest public evidence: a full randomized, double-blind, vehicle-controlled report. The eye and body pages describe smaller studies without identifying a control group, and the face serum page displays the face cream’s study results rather than a serum-specific trial.

This is where a product line can borrow credibility from one tested item. We separated the evidence by finished product.

The M4 evidence map

Product	Price / labeled supply	Published estriol strength	Public evidence shown for that finished product	What the numbers represent
M4 Face Cream Rx	$150 / 3 months	0.3%, in the study report	Full protocol DCS-102-23; 90 enrolled, 86 completed; randomized, double-blind, vehicle-controlled	Instrument results plus investigator and participant grades
M4 Face Serum Rx	$159 / 3 months	Not published on product page	Product page displays the face-cream study claims; no serum-specific controlled report found on the public page	Results borrowed from a different finished product
M4 Eye Cream Rx	$90 / 3 months	1%	Product page describes a 2025 study with 34 participants; full report not located on the public page	Primarily participant-reported percentages and page-level claims
M4 Body Treatment Rx	$195 / 3 months	0.2%	Product page describes a 2026 study with 38 participants; page does not identify a control group	Primarily participant-reported percentages and page-level claims

The face cream deserves to carry its own evidence. The rest of the line does not automatically inherit it.

The eye cream deserves a separate pause

The M4 Eye Cream page publishes a 1% estriol concentration — more than three times the face cream’s studied concentration — and applies it to the eye area. The page describes a 34-person study, but we did not find a full report linked there that would let a reader inspect design, comparator, exclusions, endpoints, or adverse-event data.

Alloy’s public eye-cream claims also use several different headline figures across pages. That does not prove the study is bad. It means the evidence package is not transparent enough to audit the way the face-cream report can be audited.

Ask for the full report before treating the face-cream trial as proof for the eye formula.

The face serum uses the face cream’s results

The serum page displays the 88%, 70%, 68%, and 57% figures from the face-cream protocol. The finished serum has peptides and hyaluronic acid and is not the same formula used in DCS-102-23.

A study of one finished product cannot be silently repurposed as a study of another finished product. The face serum may be useful. The public evidence block does not prove it.

▸ The uncomfortable retail-specification gap

Alloy’s standalone M4 face-cream page leaves the concentration and net quantity out of the buying panel. Alloy’s own study report supplies the 0.3% concentration, and its Glow & Go bundle page lists the face cream as 45 g.

So the problem is not that Alloy has never published the numbers. The problem is that the page where you make the purchase does not put the two dose-and-value numbers where you can use them.

Midi does. Its current product page publishes:

• estriol 0.3%;
• DMAE 0.3%;
• hyaluronic acid 0.5%;
• three 30 mL pumps, 90 mL total; and
• $149 for a 90-day supply.

That works out to about $1.66 per mL. Alloy’s per-mL price cannot be calculated from its public retail pages because its disclosed retail quantity is by weight and its retail pump output is not published.

Midi’s weakness is the mirror image: we did not find a randomized, vehicle-controlled finished-product trial linked from its public product page.

So the real choice is not simply “a company that tells you what is in the tube” versus “a company that tests the tube.” Alloy publishes a full ingredient list and a strong study. The sharper tradeoff is:

Midi gives you clearer retail specifications and a calculable unit price. Alloy gives you the stronger finished-product study. Neither gives you both.

If published strength, volume, pigmentation cautions, and unit-cost transparency are your priority, Midi is the cleaner fit.

→ See Midi’s current Estriol+ formulation, price, and availability

Compounded prescription product; not FDA-approved. Prescription depends on clinician review. Affiliate link — The HRT Index may earn a commission if you use it.

---

What happens if M4 does not work? Refunds, cancellation, and timing

Alloy’s Terms of Use allow a refund request within 30 days of receiving the first shipment of a product. Products cannot be returned, service and consultation charges are non-refundable, and later shipments are not refund-eligible. The M4 evidence separates most clearly from vehicle at week 12, so the refund decision arrives long before the evidence-based results decision.

That mismatch is the practical trap — not because Alloy hides the terms, but because the two clocks solve different problems.

The rules, as written in Alloy’s Terms of Use

Question	Current term
Can you request a product refund?	Yes, within 30 days after receiving the applicable shipment
Which shipment qualifies?	First shipment of each product only
Can you physically return it?	No; prescription and non-prescription products are not returnable
Are consultation or service charges refundable?	No
Is approval automatic?	No; Alloy reserves the right to verify the basis of the request
Cancel the subscription	At least 7 days before the current subscription period ends
Pause or cancel a shipment	At least 5 business days before the shipment is scheduled to process
Damaged or missing shipment	Contact Alloy within 14 days; remedy stated is replacement, not refund

There are two cancellation clocks. Put both in your calendar.

The refund clock versus the study clock

• Day 0: shipment arrives.
• By day 30: first-shipment refund request must be made.
• Week 4: the study did not show between-product differentiation.
• Week 8: the report still found no significant between-product differences.
• Week 12: the clearest estriol-versus-vehicle investigator differences appeared; objective hydration was significant.

At day 30, you are not deciding whether M4 produced the study’s 12-week result. By definition, it has not had the study’s full observation period.

You are deciding whether the early experience — irritation, pump function, texture, service, and willingness to continue — justifies keeping the subscription alive long enough to judge it.

The no-drama calendar move

The day the shipment arrives, save four dates:

1. Day 25: decide whether you need to ask about a first-shipment refund.
2. Day 30: refund-request deadline.
3. Five business days before the next shipment: shipment pause/cancel deadline.
4. Seven days before the subscription period ends: subscription cancellation deadline.

Keep the cancellation confirmation and any support response. Do not wait for week 12 to discover a refill has already processed.

▸ When this purchase is part of a bigger HRT decision

A face cream will not resolve hot flashes, night sweats, vaginal symptoms, sleep disruption, or a medication-fit question. Use Find My HRT Path when the skincare decision is sitting on top of a bigger menopause-care decision — especially when you need the “online care is not the right starting point” flag.

---

How does Alloy M4 compare with Midi, Winona, Wisp, and Musely?

Alloy has the strongest public finished-product study in this comparison. Midi has the clearest formula and volume disclosure. Winona is the only compared product combining estriol with tretinoin, but the final formula is compounded and its active strengths are not public. Wisp has the lowest listed 90-day price. Musely uses a different two-month price interval.

No seller wins every column. That is the useful answer.

Product	Listed price / supply	Strength published?	Volume published?	Other active ingredients	Finished-product controlled study linked?	Main transparency issue
Alloy M4 Face Cream Rx	$150 / 3 months	0.3% in study report, not standalone buying panel	Bundle page lists 45 g; standalone page omits quantity	None identified as additional prescription actives	Yes — randomized, double-blind, vehicle-controlled	Conflicting public pump instructions; retail unit cost cannot be independently calculated
Midi Estriol+ Face Cream	$149 / 90 days	Yes: estriol 0.3%, DMAE 0.3%, HA 0.5%	Yes: 90 mL total	DMAE, hyaluronic acid	None linked from public product page that we found	Provider makes systemic-safety claims stronger than the finished-product evidence shown on the page
Winona Estriol + Tretinoin	$150 / 3 months	No active strengths published	No net volume published	Tretinoin	None linked from public product page that we found	Page incorrectly says estriol is FDA-approved and blurs ingredient approval with finished-product approval
Wisp Estriol Face Cream	$99 / 90 days, consult included	No	No	Not clearly disclosed on public page	None linked from public product page that we found	Strength and volume unavailable, so medication fit and unit price cannot be fully assessed
Musely Aging Repair Cream	$72 auto-refill or $103 one-time / estimated 2 months; $20 first new-treatment doctor fee	Yes: estriol 0.3%	Not clearly published on the public page we verified	Vitamin C 1%, HA 0.5%, aloe	None linked from public product page that we found	Different refill interval makes simple three-month comparisons misleading

Which is best for hydration with the strongest product-specific evidence?

Alloy. The 26% objective hydration result and the vehicle-controlled design give it the best public finished-product evidence in this table.

Which is best for price and formula transparency?

Midi. It is the only product here that publishes the estriol strength, supporting-active strengths, total volume, and a 90-day price in one place. At $149 for 90 mL, the unit price is about $1.66 per mL.

Which is best if tretinoin is the feature you want?

Winona is the only compared seller combining estriol and tretinoin in one compounded cream. That can simplify a routine, but do not translate Renova’s FDA approval into approval of Winona’s product. Winona does not publish either active strength, and its finished combination is not FDA-approved.

Which has the lowest listed 90-day price?

Wisp at $99, including its consult. The tradeoff is that its public page does not publish the estriol concentration or net volume, so the medication and unit-cost comparison stops at the sticker price.

The one FDA line Winona must fix

Winona’s FAQ says estriol and tretinoin are FDA-approved active ingredients. FDA says no FDA-approved drug contains estriol. The final Winona cream is prepared by a compounding pharmacy and is not FDA-approved.

That is not a technicality. It is a YMYL correction a reasonable buyer needs before comparing the two providers.

→ See Winona’s estriol-plus-tretinoin option and read the current formulation details

Compounded prescription product; not FDA-approved. Active strengths are not published on the current product page. Tretinoin can cause irritation and photosensitivity; follow the prescriber’s directions. Affiliate link — The HRT Index may earn a commission if you use it.

For the full switching logic, use the dedicated Alloy M4 alternatives page. This review stays focused on whether M4 itself earns the $150.

---

What do real Alloy M4 customers say?

Alloy Health’s claimed Trustpilot profile showed a 4.3 TrustScore from 3,864 reviews on August 11, 2026. That profile covers Alloy’s whole business, not M4 alone. Current reviews praise easy clinician communication and delivery; other reviewers report support, shipment, interface, and supply-duration problems. None proves M4 effectiveness or safety.

We are not using testimonials as clinical evidence. The study is already stronger than a stranger’s mirror.

Alloy also says that 92% of M4 users in a 2025 survey would recommend it. The product page does not publish the survey’s sample size, response rate, recruitment method, or questionnaire. That makes it a satisfaction claim, not an efficacy endpoint.

Three useful review observations — and what they can actually tell you

“I’ve been able to communicate easily with my Dr and get a response in a very timely manner.” — verified Trustpilot reviewer, August 2026

That supports one person’s service experience. It does not prove every clinician replies at that speed.

“Easy to use site, quick responses from the doctor(s). Product arrives as scheduled.” — verified Trustpilot reviewer, July 2026

That supports one person’s onboarding and delivery experience. It does not prove treatment effectiveness.

“The estrogen face cream and eye cream don’t last as long as they say they should.” — verified Trustpilot reviewer, July 2026

That is an individual supply-duration complaint, not proof of a systematic shortfall. It matters because Alloy’s public pump instructions conflict and the standalone retail page does not publish enough dispenser data to reproduce the three-month claim.

Why we do not quote “glowing skin” as proof

A before-and-after story can be sincere and still tell you nothing about the cause. Lighting, expression, camera distance, concurrent retinoids, injectables, sunscreen, routine changes, and ordinary regression all move a skincare photo.

The M4 study already gives a better answer:

• objective hydration improved;
• machine elasticity did not;
• the investigator saw several appearance differences at week 12;
• participant ratings did not meaningfully separate the groups; and
• no adverse event occurred during 12 weeks.

That is more useful than “magic in a bottle.”

Watch the company name when reading aggregate reviews

There are unrelated businesses named Alloy. Make sure any review profile points to myalloy.com and Alloy Health before using the score. A review of metal products, jewelry, apparel, or another company does not belong in this decision.

---

Who should skip Alloy M4 or get specialist clearance first?

Skip M4 when your real goal is relief from systemic or vaginal menopause symptoms, when the recurring $150 charge is uncomfortable, or when you need an FDA-approved finished drug. Get direct clinician or specialist clearance before using it if pregnancy, cancer, unexplained bleeding, clotting, liver disease, interacting hormone treatment, or active pigment disease changes the risk decision.

We would rather lose the click than put a skincare checkout in charge of the wrong question.

Skip it because it is the wrong category

M4 will not treat hot flashes, night sweats, sleep disruption, brain fog, bone loss, urinary symptoms, vaginal dryness, or painful sex. A prescription face cream is not a substitute for systemic or local menopause treatment.

→ Find My HRT Path if skin is not the only reason you are searching.

Skip it if the price will make you ration the prescription

Do not buy a $150 three-month bottle and then invent a lower dose to force the monthly math to work. Follow the prescription label. Midi and Wisp have lower or clearer price routes, with different evidence and transparency tradeoffs.

Skip it if FDA approval is non-negotiable

There is no FDA-approved estriol drug. M4 is compounded. A prescriber can still decide it fits, but the regulatory category will not change at checkout.

Get explicit specialist guidance first when your history changes the decision

That includes:

• a personal history of breast, uterine, ovarian, or another estrogen-sensitive cancer;
• current tamoxifen or aromatase-inhibitor use;
• unexplained or postmenopausal bleeding;
• significant clotting, stroke, or liver history;
• pregnancy, breastfeeding, or trying to conceive;
• active melasma or a strong history of hormone-triggered pigmentation; or
• a complex systemic or vaginal hormone regimen that the online prescriber may not fully see.

The M4 trial was not designed to settle those questions.

Do not make tretinoin an automatic prerequisite

Daily broad-spectrum sunscreen is the baseline for any photoaging plan. Tretinoin is a prescription option with an FDA-approved fine-wrinkle product, but it is not right for everyone and it can irritate skin. The correct sequence is not “everyone must use tretinoin first.” It is “define the goal, review contraindications and tolerance, then choose the evidence and formulation that fit.”

---

What we actually verified

This review is based on Alloy’s current product pages, Terms of Use, knowledge base, full clinical report, FDA materials, current competitor product pages, peer-reviewed literature, and current company-review data. We hold no commercial relationship with Alloy and did not use the product ourselves.

Verified on August 11, 2026

• M4’s listed $150 price and three-month supply label.
• The full M4 ingredient list on Alloy’s standalone product page.
• The 0.3% estriol strength in protocol DCS-102-23.
• The study’s design, sponsor, population, exclusions, dosing, objective instruments, investigator grading, participant grading, serum results, melanin result, TEWL result, and adverse-event statement.
• That the 88% claim came from the investigator’s between-group elasticity grade, while the mechanical elasticity measure did not consistently change.
• That participants used one assigned product each; they did not directly test all three formulas.
• The study dispenser’s 45 mL capacity and 0.3 mL pump output.
• The Glow & Go bundle page’s 45 g retail face-cream listing.
• Alloy’s conflicting public one-pump, two-pump, and three-pump reference amounts.
• Alloy’s refund, return, subscription-cancellation, shipment-cancellation, and damaged-shipment terms.
• That the standalone M4 buying page did not visibly identify the product as compounded or not FDA-approved.
• FDA’s statement that no FDA-approved drug contains estriol.
• Midi’s $149/90-day price, 90 mL total volume, and active formula: estriol 0.3%, DMAE 0.3%, hyaluronic acid 0.5%.
• Winona’s $150/three-month price, compounded status, published ingredient list, unpublished active strengths, and inaccurate FDA statement about estriol.
• Wisp’s $99/90-day price with consult included and lack of public strength/volume disclosure.
• Current M4 line prices and the public evidence shown for face cream, serum, eye cream, and body treatment.
• Alloy Health’s current Trustpilot company profile, count, score, and response behavior.

Could not independently verify from current public pages

• A separate first-order skincare consultation fee. The M4 page lists $150 and $0 unlimited doctor access; confirm the final checkout total before payment.
• The exact retail pump output and total number of full pumps in the standalone M4 bottle.
• A retail mL quantity equivalent to the bundle page’s 45 g listing.
• A complete, product-specific state list for M4. Check availability during intake before payment.
• The exact dispensing pharmacy for an individual M4 prescription. Alloy’s terms name three pharmacies, but the assigned pharmacy can vary.
• A full public study report for M4 Eye Cream or M4 Body Treatment.
• A serum-specific controlled trial supporting the results displayed on the M4 Face Serum page.
• Long-term M4 safety, zero systemic absorption, or effectiveness when layered with systemic HRT, retinoids, vitamin C, acids, injectables, laser, or other excluded treatments.
• Firsthand product results. We did not use M4 and will not pretend we did.

How we assess the provider and product

The HRT Index Verification Standard is our documented process: read every published price, keep FDA-approved and compounded options separate, verify state availability and insurance where the provider publishes them, and re-check on a fixed schedule — top providers monthly and the full roster quarterly.

We evaluate in this order: clinical legitimacy, care quality, medication fit, price transparency, access.

We do not reduce M4 or any provider to an invented numeric score. A single number would hide the exact tradeoffs this page exists to show.

---

Alloy M4 face cream review: the bottom line

M4 is worth considering when hydration and smoother texture are the goal, daily sunscreen is already handled, $150 every three months is sustainable, and you accept a compounded prescription with a limited but unusually transparent finished-product study. It is not an 88% machine-measured elasticity treatment, an FDA-approved wrinkle drug, or proven zero-absorption skincare.

Here is the clean decision:

Choose Alloy M4 when you want the strongest public finished-product study in this direct-to-consumer estriol-cream comparison. The machine-measured hydration result is real. The sponsor published the full report, including findings that weaken the marketing.

Choose Midi when published strength, volume, full active formula, pigmentation cautions, and calculable unit cost matter more than having a controlled finished-product trial.

Consider Winona when a prescriber agrees that a combined compounded estriol-and-tretinoin routine fits your fine-line goal — while understanding that the final formula is not FDA-approved, the active strengths are not public, and Winona’s current estriol approval statement is wrong.

Choose none of them yet when the problem is not your face. Hot flashes, sleep, vaginal symptoms, bleeding, cancer history, pregnancy, or a complex hormone regimen deserve the right care path before a skin subscription.

Your next step, based on the decision you just made

• The study and tradeoffs fit: See Alloy’s current M4 price and start the skin assessment — we earn nothing from this link.
• You want the clearest formula and unit price: See Midi Estriol+ — compounded prescription; not FDA-approved; affiliate link.
• You want a combined estriol/tretinoin option: Review Winona’s current product details — compounded prescription; not FDA-approved; affiliate link.
• You are not sure skincare is the real decision: Use Find My HRT Path.

---

Frequently asked questions

Does Alloy M4 face cream really work?

It depends on the outcome. In Alloy’s 12-week randomized trial, objective skin water content increased 26% in the 0.3% estriol group, p=0.001. Mechanical elasticity did not consistently change, wrinkles were not among the significant estriol wins, and participant ratings did not meaningfully separate the three assigned products.

Is Alloy M4 FDA approved?

No. M4 is a compounded prescription drug. FDA states there is no FDA-approved drug containing estriol, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing the way it reviews approved drugs.

How much estriol is in Alloy M4?

The clinical study report identifies the face cream as 0.3% estriol. The standalone retail page identifies estriol but does not state the percentage in its buying panel. Alloy’s eye cream is listed at 1% and the body treatment at 0.2%.

What does the 88% M4 claim mean?

It is the week-12 difference between the estriol and vehicle groups in the investigator’s 5-point visual and tactile elasticity grade. It is not 88% of participants, not an 88% change from baseline, and not an 88% increase on the mechanical elasticity instrument.

Did the study find a machine-measured elasticity improvement?

No consistent change was found in the estriol, estradiol, or vehicle group on the mechanical elasticity measurement.

Did the study find a hydration improvement?

Yes. Corneometry showed a 26% increase in skin water content from baseline in the estriol group at week 12, p=0.001. The vehicle group did not significantly improve on that measurement.

Did M4 reduce wrinkles in the study?

Wrinkles were measured, but they were not listed among the statistically significant estriol improvements versus baseline or significant estriol-versus-vehicle differences in the report’s discussion.

Did anyone have an adverse event?

The report says no adverse event occurred during the 12-week study and no tolerability issue was identified. That is reassuring for the study period; it is not a long-term safety database.

What happened to the skin-barrier measurement?

The estriol group had a statistically significant 13% increase in TEWL at week 12, meaning more water left the skin. The report called the estradiol and vehicle groups barrier-neutral. No irritation occurred, so this is a contradictory instrument finding rather than proof of clinical skin damage.

How much does Alloy M4 cost?

Alloy lists it at $150 for one bottle described as a three-month supply. There is no one-month option on the current page. The page does not display a separate skincare consultation charge; confirm the final order total before payment.

Does insurance cover Alloy M4?

Alloy uses a cash-pay model and does not present M4 as an insurance-billed product. The page displays an HSA/FSA Eligible badge, but the account administrator decides whether an expense qualifies and what documentation is required.

How long does one M4 bottle last?

Alloy sells it as a three-month supply. The public retail information is not sufficient to independently calculate the number of nights because public pump instructions conflict, the standalone page omits pump output, and the retail quantity disclosed on a bundle page is 45 g while the study dispenser was 45 mL.

How many pumps of M4 should I use?

Follow your prescription label. Alloy’s current public materials give one pump in a help-center answer, two pumps in its skincare routine, and three pumps in the study protocol. The research dose is not automatically your prescribed retail dose.

Was the M4 eye area studied?

The face-cream study protocol included the forehead, cheeks, under/around the eyes, and neck. That does not mean cream should be placed in the eyes, and it does not make the separate 1% eye cream equivalent to the 0.3% face cream. Follow the dispensing label.

How long does M4 take to work?

The study found no significant between-product differences at weeks 4 or 8. The clearest differentiation from vehicle occurred at week 12. Alloy’s broader skincare page also uses an eight-week claim, but the finished face-cream report supports week 12 as the stronger comparison point.

Does M4 raise estrogen levels?

In the 12-week study, serum estriol did not change significantly. That supports minimal measured systemic exposure under the study conditions. It does not prove zero absorption for every user or long-term use.

Can I use M4 if I am already on HRT?

Alloy markets it for use with or without HRT, but the trial excluded current HRT users and enrolled women who had never taken systemic HRT. Tell the prescriber your complete hormone regimen and let that clinician decide.

Can I use M4 after breast cancer?

That decision needs direct guidance from the clinician who knows your cancer history, including the oncology team when applicable. The M4 trial’s 30 healthy estriol participants over 12 weeks do not answer that question.

Can M4 cause melasma?

The M4 study found no pigmentation increase over 12 weeks. That does not establish zero long-term risk, and Midi warns that estriol may exacerbate melasma. If you have active or hormone-triggered melasma, ask a dermatologist before starting.

Can I use M4 with tretinoin, retinol, vitamin C, or acids?

Ask the prescriber how to sequence them. The M4 trial excluded retinoids, vitamin C, AHAs, and salicylic acid, so it does not establish combined effectiveness or tolerability.

Can I put vaginal estrogen cream on my face instead?

Do not repurpose a prescription. Vaginal products have different strengths, bases, labels, applicators, and intended sites. Use a product only as directed by the clinician who prescribed it.

How do I cancel Alloy M4?

Alloy’s current terms say to cancel the subscription by email or through the account dashboard at least seven days before the current period ends. A shipment pause or cancellation must be submitted at least five business days before it is scheduled to process. Save the confirmation.

Can I get an Alloy M4 refund?

You may request a refund within 30 days of receiving the first shipment of that product. Later shipments are not eligible, products cannot be returned, service and consultation charges are non-refundable, and Alloy may verify the basis of the request.

Is Alloy M4 available in my state?

Alloy says its services are subject to state availability but does not publish a complete M4-specific state list on the product page. Check eligibility before payment.

Is M4 better than Midi?

Alloy has the stronger public finished-product study. Midi has the clearer retail specification: 0.3% estriol, 0.3% DMAE, 0.5% hyaluronic acid, 90 mL, and $149 for 90 days. Choose according to evidence depth versus formulation and unit-cost transparency.

Is M4 better than Winona?

Alloy has the controlled finished-product trial. Winona combines estriol with tretinoin, but its final formula is compounded, the active strengths are not public, and the product does not inherit Renova’s FDA approval. The better fit depends on whether hydration evidence or a combined retinoid routine is the priority.

What does M4 stand for?

Mega Miracle Menopause Moisturizer.

---

Still not sure which HRT program is right for you? Take our free matching quiz.

→ Find My HRT Path

---

Related menopause and HRT guides

Keep comparing evidence, safety, price, and care routes before you start an online prescription:

• Read the full Alloy menopause review
• Review Alloy pricing and subscription costs
• Compare Midi with Alloy
• Understand compounded versus FDA-approved treatment
• Read the guide to menopause and dry skin
• Find your best-fit HRT path

Sources

All provider pages and commercial terms were accessed and re-verified on August 11, 2026 unless otherwise stated.

1. Alloy Health — M4 Face Cream Rx
2. Alloy Health — M4 skincare category
3. Alloy Health — Glow & Go Set
4. Alloy Health — M4 Face Serum Rx
5. Alloy Health — M4 Eye Cream Rx
6. Alloy Health — M4 Body Treatment Rx
7. Alloy Health — Terms of Use, last revised May 28, 2026
8. Dermatology Consulting Services / Alloy Women’s Health — Protocol DCS-102-23, full 34-page report
9. FDA — Menopause: compounded hormones and estriol
10. FDA — Compounding and the FDA: Questions and Answers
11. DailyMed — Renova (tretinoin cream) 0.02% prescribing information
12. eCFR — 21 CFR Part 347, skin-protectant drug products
13. Kainz C, et al. “When applied to facial skin, does estrogen ointment have systemic effects?” Archives of Gynecology and Obstetrics. 1993;253(2):71–74. PMID 8215610.
14. Schmidt JB, et al. “Treatment of skin aging with topical estrogens.” International Journal of Dermatology. 1996;35(9):669–674. PMID 8876303.
15. Creidi P, et al. “Effect of a conjugated oestrogen cream on ageing facial skin: a comparative study with a placebo cream.” Maturitas. 1994;19(3):211–223. PMID 7799828.
16. Midi Health — Estriol+ Face Cream
17. Winona — Estriol Face Cream with Tretinoin
18. Wisp — Estriol Face Cream
19. Musely — Aging Repair Cream
20. Trustpilot — Alloy Health company profile